The sponsors did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the article. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health, American Society of Clinical Oncology (ASCO), or the ASCO Foundation. DH, whose role in the study was to confirm and validate the data analyses, owns stock in Pfizer, Inc (New York, NY), the makers of irinotecan.
Primary contacts and clinical centers that participated in the CALGB clinical trial included Lee S. Schwartzberg, Baptist Cancer Institute Community Clinical Oncology Program, TN (supported by CA71323); Stephen Grubbs, Christiana Care Health Services, Inc, Community Clinical Oncology Program, Wilmington, DE (supported by CA45418); Harold J. Burstein, Dana-Farber Cancer Institute, Boston, MA (supported by CA32291); Konstantin Dragnev, Dartmouth Medical School, Norris Cotton Cancer Center, Lebanon, NH (supported by CA04326); Jeffrey Crawford, Duke University Medical Center, Durham, NC (supported by CA47577); Minetta C. Liu, Georgetown University Medical Center, Washington, DC (supported by CA77597); Jeffrey K. Giguere, Cancer Centers of the Carolinas, Greenville, SC (supported by CA29165); Jeffrey Kirshner, Hematology-Oncology Associates of Central New York Community Clinical Oncology Program, Syracuse, NY (supported by CA45389); Kanti R. Rai, Long Island Jewish Medical Center, Lake Success, NY (supported by CA35279); Jeffrey W. Clark, Massachusetts General Hospital, Boston, MA (supported by CA32291); Clifford A. Hudis, Memorial Sloan-Kettering Cancer Center, New York, NY (supported by CA77651); Lewis R. Silverman, .D., Mount Sinai School of Medicine, New York, NY (supported by CA04457); John A. Ellerton, Nevada Cancer Research Foundation CCOP, Las Vegas, NV (supported by CA35421); William Sikov, Rhode Island Hospital, Providence, RI (supported by CA08025); Ellis Levine, Roswell Park Cancer Institute, Buffalo, NY (supported by CA59518); James N. Atkins, Southeast Cancer Control Consortium, Inc, CCOP, Goldsboro, NC (supported by CA45808); Stephen L. Graziano, State University of New York Upstate Medical University, Syracuse, NY (supported by CA21060); Clara D. Bloomfield, The Ohio State University Medical Center, Columbus, OH (supported by CA77658); Barbara A. Parker, University of California at San Diego, San Diego, CA (supported by CA11789); Hedy L. Kindler, University of Chicago, Chicago, IL (supported by CA41287); David J. Peace, University of Illinois MBCCOP, Chicago, IL (supported by CA74811); Daniel A. Vaena, University of Iowa, Iowa City, IA (supported by CA47642); Martin Edelman, University of Maryland Greenebaum Cancer Center, Baltimore, MD (supported by CA31983); William V. Walsh, University of Massachusetts Medical School, Worcester, MA (supported by CA37135); Bruce A. Peterson, University of Minnesota, Minneapolis, MN (supported by CA16450); Michael C. Perry, University of Missouri/Ellis Fischel Cancer Center, Columbia, MO (supported by CA12046); Anne Kessinger, University of Nebraska Medical Center, Omaha, NE (supported by CA77298); Thomas C. Shea, University of North Carolina at Chapel Hill, Chapel Hill, NC (supported by CA47559); Harvey B. Niell, University of Tennessee Memphis, Memphis, TN (supported by CA47555); Marc S. Greenblatt, University of Vermont, Burlington, VT (supported by CA77406); David D. Hurd, Wake Forest University School of Medicine, Winston-Salem, NC (supported by CA03927); Brendan M. Weiss, Walter Reed Army Medical Center, Washington, DC (supported by CA26806); Nancy Bartlett, Washington University School of Medicine, St. Louis, MO (supported by CA77440); John Leonard, Weill Medical College of Cornell University, New York, NY (supported by CA07968).